An antimicrobial peptide based on gramicidin S derivative design and its preparation method and application

By designing the antibacterial peptide PF-15, the hemolytic toxicity and cytotoxicity problems of breccinidin S were solved, and higher biocompatibility and resistance were achieved, the preparation process was simplified, and suitable as a clinical antibacterial drug.

CN117886893BActive Publication Date: 2024-11-12ZUNYI MEDICAL UNIV ZHUHAI CAMPUS
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202311840973.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-12-28
Publication Date
2024-11-12
Estimated Expiration
2043-12-28

AI Technical Summary

Technical Problem

Existing antibacterial cyclic peptides such as breccinin S have high hemolytic toxicity and cytotoxicity, which limits its clinical application prospects. At the same time, its industrial preparation is complex and costly.

Method used

Design an antimicrobial peptide PF-15 derived from breccinidin S, with its amino acid sequence as Pro-Val-Arg-Leu-dPhe-Pro-Val-Arg-Leu-dPhe, Prepared by polypeptide solid phase synthesis method, it has lower hemolytic toxicity and cytotoxicity, and retains antibacterial activity.

Benefits of technology

PF-15 exhibits better biocompatibility in vitro and peripheral blood environments, significantly improves the therapeutic index, is well resistant to Gram-positive bacteria, can bind to intracellular receptors to inhibit ATP production and promote ROS generation significantly reduces the toxicity of cell membranes and simplifies industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117886893B_ABST
    Figure CN117886893B_ABST
Patent Text Reader

Abstract

The present invention discloses an antimicrobial peptide based on gramicidin S derivative design and its preparation method and application, and relates to the field of biotechnology. The amino acid sequence of the antimicrobial peptide PF-15 of the present invention is shown in SEQ ID NO.1. The antimicrobial peptide PF-15 consists of 15 amino acid residues, contains 3 repeated pentapeptide sequences, has a molecular weight of 1856.35 Daltons, and has a typical α-helical structure and amphipathic characteristics. The antimicrobial peptide PF-15 of the present invention has lower hemolytic toxicity and cytotoxicity than gramicidin S (GS), and can effectively retain the antibacterial mechanism of the parent peptide, has good resistance to common clinical Gram-positive bacteria, and can be used as the main component of anti-infective disease drugs for clinical bacteremia treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to an antimicrobial peptide designed based on gramicidin S derivatives, and a preparation method and application thereof. Background Art

[0002] Antimicrobial peptides (AMPs) are a class of biological molecules existing in nature. According to their structural characteristics, they can be divided into linear peptides and cyclic peptides, and are widely used in pathogenic microbial infections. Gramicidin S (GS) is a natural cationic cyclic decapeptide (cyclo(-Val-Orn-Leu-D-Phe-Pro-)2) with broad-spectrum antimicrobial activity. It is composed of two repeated pentapeptide sequences connected end to end. It has an antiparallel β-folded structure, and the hydrophobic Val and Leu residues and the hydrophilic Orn residues are distributed on both sides of the macrocyclic plane, thus having typical amphiphilic characteristics.

[0003] Related studies have shown that GS inhibits bacterial growth or kills bacteria mainly by destroying the cell membrane or affecting the function of the cell membrane. When GS interacts with bacteria, it can induce the instantaneous collapse of the bacterial cell membrane to form discontinuous holes, thereby causing cytoplasm leakage. Compared with traditional antibiotics, it has better resistance to drug resistance. However, this antibacterial mechanism often brings about relatively serious hemolytic toxicity, which greatly limits the clinical application prospects of GS. Maintaining or enhancing the antibacterial activity of GS-type cyclic peptides while reducing their hemolytic toxicity and cytotoxicity to improve the therapeutic index is a hot topic in this field. In addition, compared with the relatively mature industrial preparation advantages of linear antimicrobial peptides, the artificial synthesis of GS-type cyclic peptides requires further separation and purification of the head and tail rings based on the linear peptide precursor, which greatly increases the difficulty and cost of synthesis.

[0004] Therefore, the design of highly active antimicrobial cyclic peptide derivatives represented by GS to obtain linear antimicrobial peptides with excellent antimicrobial activity and better biosafety has important research value and development prospects. Summary of the invention

[0005] The present invention aims to solve at least one of the technical problems existing in the prior art. To this end, the present invention proposes an antimicrobial peptide PF-15 based on the design of gramicidin S derivative, which has lower hemolytic toxicity and cytotoxicity than gramicidin S (GS), and can effectively retain the antibacterial mechanism of the parent peptide, that is, it binds to the receptor protein inside the cell to inhibit the production of adenosine triphosphate (ATP) while promoting the generation of reactive oxygen species (ROS).

[0006] The invention also provides a method for preparing the antimicrobial peptide PF-15.

[0007] The invention also provides a biomaterial.

[0008] The present invention also proposes an application of the antimicrobial peptide PF-15 or biomaterial in the preparation of antimicrobial products.

[0009] The invention also provides an antibacterial drug.

[0010] In a first aspect of the present invention, there is provided an antimicrobial peptide PF-15 derived from gramicidin S, wherein the amino acid sequence of the antimicrobial peptide PF-15 is shown in SEQ ID NO.1.

[0011] The antimicrobial peptide PF-15 according to the embodiment of the present invention has at least the following beneficial effects:

[0012] The antimicrobial peptide PF-15 designed based on GS derivatives in the present invention is mainly composed of hydrophobic amino acids and basic amino acids, and possesses the key factors for natural AMPs to exert antibacterial effects: positive charge, hydrophobic domain, amphiphilicity, α-helical secondary conformation, etc. In addition, PF-15 maintains the antibacterial activity of the GS nucleus well in vitro and in peripheral blood environments. At the same time, according to hemolytic toxicity experiments and cytotoxicity experiments, it can be seen that PF-15 has better biocompatibility than GS, significantly improves its therapeutic index, has relatively lower hemolytic toxicity and cytotoxicity to human erythrocytes and HUVECs, and has good resistance to common clinical Gram-positive bacteria (such as Staphylococcus aureus and Enterococcus faecium), and is expected to be developed into an antibacterial drug for clinical use.

[0013] In some embodiments of the present invention, the phenylalanine in the antimicrobial peptide PF-15 is D-phenylalanine.

[0014] D-type amino acids are mostly artificial amino acids, which can better change the amphipathicity of antimicrobial peptides and improve the therapeutic index of antimicrobial peptides.

[0015] In some embodiments of the present invention, the amino acid sequence of the antimicrobial peptide PF-15 is as follows:

[0016] Pro-Val-Arg-Leu-dPhe-Pro-Val-Arg-Leu-dPhe-Pro-Val-Arg-Leu-dPhe.

[0017] In some embodiments of the present invention, the antimicrobial peptide PF-15 has an α-helical structure.

[0018] The antimicrobial peptide PF-15 of the present invention is composed of 15 amino acid residues, contains 3 repeated pentapeptide sequences, has a molecular weight of 1856.35 Daltons, and has a typical α-helical structure and amphipathic characteristics.

[0019] The second aspect of the present invention provides a method for preparing the antimicrobial peptide PF-15 described in the first aspect, comprising preparing the antimicrobial peptide PF-15 by using a polypeptide solid phase synthesis method.

[0020] The preparation method according to the embodiment of the present invention has at least the following beneficial effects: the antimicrobial peptide PF-15 prepared by the polypeptide solid phase synthesis method has a high purity, which can reach more than 95%.

[0021] In some embodiments of the present invention, the polypeptide solid phase synthesis method includes Fmoc polypeptide solid phase synthesis method.

[0022] In some embodiments of the present invention, the method for preparing the antimicrobial peptide PF-15 specifically comprises the following steps:

[0023] Firstly, the amino acid Fmoc-dPhe-OH is loaded on the first position of the dichlororesin, and then the amino acids are sequentially extended from the C-terminus to the N-terminus according to the polypeptide sequence of the antimicrobial peptide PF-15, and deprotection, condensation and deprotection operations are repeated in the process until the N-terminus Pro is reached, and finally the resin is cut, precipitated, separated and purified, and dried to obtain the product.

[0024] The third aspect of the present invention provides a biomaterial, wherein the biomaterial is any one of A1) to A4):

[0025] A1), a nucleic acid molecule encoding the antimicrobial peptide PF-15 described in the first aspect;

[0026] A2), an expression cassette containing the nucleic acid molecule described in A1);

[0027] A3), a recombinant vector containing the nucleic acid molecule described in A1) or the expression cassette described in A2);

[0028] A4), a recombinant cell containing the nucleic acid molecule described in A1), the expression cassette described in A2) or the recombinant vector described in A3).

[0029] The fourth aspect of the present invention provides the use of the antimicrobial peptide PF-15 described in the first aspect or the biomaterial described in the third aspect in the preparation of an antimicrobial product.

[0030] In some embodiments of the invention, the antimicrobial product comprises a drug for treating bacteremia.

[0031] In some embodiments of the present invention, the antibacterial product comprises an anti-Gram-positive bacteria product.

[0032] In some embodiments of the present invention, the Gram-positive bacteria include at least one of Staphylococcus aureus and Enterococcus faecium.

[0033] In some embodiments of the present invention, the staphylococci include but are not limited to Staphylococcus aureus (S. aureus), Methicillin-Resistant Staphylococcus aureus (MRSA), and Methicillin-Resistant Staphylococcus epidermidis (MRSE).

[0034] The PF-15 prepared by the present invention has excellent antibacterial effects on multiple Gram-positive bacteria, especially S. aureus. Combined with the antibacterial activity experiments of GS on various Gram-positive bacteria, it can be seen that the PF-15 prepared by the present invention can have similar antibacterial activity as the parent peptide.

[0035] In addition, the antimicrobial peptide PF-15 of the present invention, like GS, can interact with lipoteichoic acid (LTA) on the surface of the cell wall of S. aureus, induce bacterial cell membrane potential to escape and change cell membrane permeability, and after entering the interior of S. aureus, both can interact with its internal receptor protein to inhibit ATP generation and promote the increase of ROS levels, ultimately leading to bacterial death. In addition, it is worth noting that, compared with GS, the PF-15 of the present invention binds more tightly to LTA and can directly destroy the integrity of the cell membrane, showing a more significant physical effect.

[0036] In some embodiments of the present invention, the Enterococcus faecium includes but is not limited to Enterococcus faecium (E. faecium) and Multidrug-Resistant Enterococcus faecium (MDR E. faecium).

[0037] The fifth aspect of the present invention provides an antibacterial drug comprising the antimicrobial peptide PF-15 or a pharmaceutically acceptable salt thereof as described in any one of the first aspects.

[0038] In some embodiments of the present invention, the antibacterial drug further comprises an antibiotic and / or a pharmaceutically acceptable excipient.

[0039] In some embodiments of the present invention, the antibiotic includes at least one of imipenem (Imp), vancomycin (Van), and cefotaxime (Cef).

[0040] In some preferred embodiments of the present invention, the antibiotic comprises vancomycin.

[0041] In the in vivo experiment of MRSA-induced bacteremia, PF-15 showed good antibacterial effect, and when it was used in combination with vancomycin, it could effectively reduce the dosage of antibiotics.

[0042] In some embodiments of the present invention, the pharmaceutically acceptable salt includes but is not limited to at least one of an inorganic acid salt and an organic acid salt.

[0043] The inorganic acid salt includes but is not limited to at least one of hydrochloride, hydrobromide, nitrate, sulfate and phosphate.

[0044] The organic acid salt includes, but is not limited to, at least one of formates, acetates, propionates, benzoates, maleates, fumarates, succinates, tartrates, citrates, alkyl sulfonates, and aryl sulfonates.

[0045] In some embodiments of the present invention, the alkyl sulfonate includes but is not limited to at least one of methyl sulfonate and ethyl sulfonate.

[0046] In some embodiments of the present invention, the aryl sulfonate includes but is not limited to at least one of benzene sulfonate and p-toluene sulfonate.

[0047] In some embodiments of the present invention, the pharmaceutically acceptable excipients are conventional excipients in the pharmaceutical field.

[0048] In some embodiments of the present invention, the pharmaceutically acceptable excipients include at least one of a diluent, an excipient, a filler, a binder, a disintegrant, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant, a sweetener and a flavoring agent.

[0049] In some embodiments of the invention, the excipient comprises water.

[0050] In some embodiments of the present invention, the filler comprises at least one of starch and sucrose.

[0051] In some embodiments of the present invention, the binder includes at least one of a cellulose derivative, alginate, gelatin and polyvinyl pyrrolidone.

[0052] In some embodiments of the invention, the humectant comprises glycerin.

[0053] In some embodiments of the present invention, the disintegrant comprises at least one of agar, calcium carbonate and sodium bicarbonate.

[0054] In some embodiments of the invention, the absorption enhancer comprises a quaternary ammonium compound.

[0055] In some embodiments of the invention, the surfactant comprises cetyl alcohol.

[0056] In some embodiments of the present invention, the adsorption carrier includes at least one of kaolin and bentonite.

[0057] In some embodiments of the present invention, the lubricant includes at least one of talc, calcium stearate, magnesium stearate and polyethylene glycol.

[0058] In some embodiments of the present invention, the dosage form of the drug is any conventional dosage form in the art.

[0059] In some embodiments of the present invention, the dosage form of the drug is in the form of solid, semisolid or liquid, and can be an aqueous solution, non-aqueous solution or suspension.

[0060] In some embodiments of the present invention, the dosage form of the drug is tablets, capsules, soft capsules, granules, pills, oral liquids, dry suspensions, pellets, dry extracts, injections or infusions.

[0061] In some embodiments of the present invention, the drug may be administered by any conventional method in the art, including but not limited to injection or oral administration.

[0062] In some embodiments of the present invention, the injection administration can be intravenous injection, intramuscular injection, intraperitoneal injection, intradermal injection or subcutaneous injection.

[0063] Other features and advantages of the present invention will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:

[0065] Figure 1 This is the hydrogen nuclear magnetic resonance spectrum of the PF-15 white powder prepared in Example 1 of the present invention;

[0066] Figure 2 The HPLC analysis results of the antimicrobial peptide PF-15 of the present invention;

[0067] Figure 3 This is the MS analysis result of the antimicrobial peptide PF-15 of the present invention;

[0068] Figure 4The helical graph models of the antimicrobial peptides PF-15 and GS of the present invention, wherein the upper graph is the antimicrobial peptide PF-15 and the lower graph is the antimicrobial peptide GS;

[0069] Figure 5 This is a characterization diagram of the minimum inhibitory concentration of the antimicrobial peptide PF-15 and GS of the present invention against Staphylococcus aureus, wherein A is PF-15 and B is GS;

[0070] Figure 6 This is a characterization diagram of the minimum bactericidal concentration of the antimicrobial peptides PF-15 and GS of the present invention against Staphylococcus aureus;

[0071] Figure 7 The time-killing curve of the antimicrobial peptides PF-15 and GS of the present invention against Staphylococcus aureus, wherein A is PF-15 and B is GS;

[0072] Figure 8 The results of the test of the inhibitory ability of the antimicrobial peptides PF-15 and GS of the present invention on biofilms;

[0073] Fig. 9 The results of the hemolytic toxicity test of the antimicrobial peptides PF-15 and GS on human erythrocytes;

[0074] Fig.10 The results of the cytotoxicity test of the antimicrobial peptides PF-15 and GS of the present invention on HUVECs;

[0075] Fig.11 The changes of intracellular ROS levels in S. aureus after treatment with different concentrations of antimicrobial peptides PF-15 and GS, where A is PF-15 and B is GS;

[0076] Fig.12 The changes of S. aureus cell membrane integrity after treatment with different concentrations of antimicrobial peptides PF-15 and GS, where A is PF-15 and B is GS;

[0077] Fig.13 The changes of ATP content in S. aureus cell membrane after treatment with different concentrations of antimicrobial peptide PF-15 and GS;

[0078] Fig.14 The changes of membrane potential of S. aureus cells after treatment with different concentrations of antimicrobial peptide PF-15 and GS;

[0079] Fig.15 The binding ability of the antimicrobial peptides PF-15 and GS of the present invention to LTA is detected, wherein A is PF-15 and B is GS;

[0080] Fig.16 This is the in vivo antibacterial activity test result of the present invention. DETAILED DESCRIPTION

[0081] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0082] In the description of the present invention, the description with reference to the terms "one embodiment", "some embodiments", "illustrative embodiments", "examples", "specific examples", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner.

[0083] The term "amino acid" refers to the basic unit that constitutes protein, which gives protein a specific molecular structure and makes its molecule have biochemical activity. For example, the "amino acid" used in the present invention includes the following 20 natural amino acids: alanine (Ala or A), glycine (Gly or G), isoleucine (Ile or I), asparagine (Asn or N), arginine (Arg or R), lysine (Lys or K), cysteine ​​(Cys or C), aspartic acid (Asp or D), glutamic acid (Glu or E), glutamine (Gln or Q), histidine (His or H), leucine (Leu or L), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), valine (Val or V) and tyrosine (Tyr or Y).

[0084] Unless otherwise specified, "room temperature" in the present invention means 25°C±5°C.

[0085] Unless otherwise specified, "about" in the present invention means that the allowable error is within ±2%.

[0086] If the specific conditions are not specified in the examples, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. If the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be purchased commercially.

[0087] Design idea of ​​antimicrobial peptide PF-15 of the present invention

[0088] Based on the previous study on GS cyclization, it was shown that the precursor linear peptide has a dominant conformation, and the linear peptide of a specific sequence has a spatial structural feature similar to that of a cyclic peptide. In the GS peptide sequence, dPhe-Pro constitutes the β-turn structure of GS, while Val-Orn-Leu constitutes an antiparallel β-folding structure. The present invention found that the GS precursor linear peptide (Pro-Val-Orn-Leu-dPhe-Pro-Val-Orn-Leu-dPhe) theoretically obtained by breaking from the β-turn will retain the GS conformational features to the greatest extent, which is an important structural basis for maintaining high antibacterial activity. Subsequently, the present invention replaced Orn with Arg, which has a stronger positive charge, and considered superimposing repeated pentapeptide fragments to enhance the α-helical structural features of the linear peptide, thereby obtaining the antimicrobial peptide PF-15, whose amino acid sequence is Pro-Val-Arg-Leu-dPhe-Pro-Val-Arg-Leu-dPhe-Pro-Val-Arg-Leu-dPhe. The PF-15 is composed of 15 amino acid residues, contains 3 repeated pentapeptide sequences, has a molecular weight of 1856.35 Daltons, and has a typical α-helical structure and amphipathic characteristics.

[0089] Example 1: Antimicrobial peptide PF-15 and its preparation method

[0090] This embodiment provides an antimicrobial peptide PF-15 derived from gramicidin S, which is obtained by replacing Orn in the peptide sequence with Arg and adding a specific peptide segment (dF-PVRL) on the basis of gramicidin S (GS for short). The antimicrobial peptide PF-15 is composed of 15 amino acid residues, contains 3 repeated pentapeptide sequences, has a molecular weight of 1856.35 Daltons, has a typical α-helical structure and amphipathic characteristics, and its specific amino acid sequence is as follows:

[0091] Pro-Val-Arg-Leu-dPhe-Pro-Val-Arg-Leu-dPhe-Pro-Val-Arg-Leu-dPhe;

[0092] The abbreviated form of the amino acid sequence is: PVRLFPVRLFPVRLF (SEQ ID NO. 1), wherein F is D-phenylalanine.

[0093] This embodiment also provides a method for preparing the above PF-15, which specifically comprises the following steps:

[0094] (1) Take 1.0 g of dichlororesin (loading value 1.08 mmol / g) and dissolve it in dichloromethane for 15 min, then separate the solvent; continue to add dichloromethane to wash 3 times, each time for 1 min, and separate the solvent after washing is completed. Dissolve Fmoc-dPhe-OH (3.24mmol, 3eq.) and DIEA (3.56mmol, 3.3eq.) in dichloromethane and add to the reaction flask. After 10min, add DIEA (7.13mmol, 6.6eq.) and react at room temperature for 3h. After the reaction, separate the reaction solution, wash the resin with dichloromethane for 4 times, take a small amount of resin, dry it and treat it with 20% piperidine for 30min, detect the absorbance of the reaction solution at 290nm, calculate the loading value of 0.7-0.9mmol / g to be qualified, then add blocking solution (DCM: MeOH: DIEA = 8: 1.5: 0.5) to block the resin; wash the resin with DMF for 5 times, add 15mL deprotection solution (DBU: piperidine: DMF = 2: 5: 93) and react for 20min, separate the reaction solution, wash with DMF, take a small amount of resin and check it for positive Kaiser indene test;

[0095] (2) Starting from the second amino acid Fmoc-Leu-OH, it was mixed with DIC (3 eq.) and HOBt (3 eq.) and dissolved in DMF. After condensation at room temperature for 2.5 h, the above deprotection, condensation and deprotection operations were repeated; the peptide chain was extended in the order of Fmoc-Arg(Pbf)-OH, Fmoc-Val-OH, Fmoc-Pro-OH, Fmoc-dPhe-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Val-OH, Fmoc-Pro-OH, Fmoc-dPhe-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Val-OH, Fmoc-Pro-OH, Fmoc-dPhe-OH, Fmoc-Leu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Val-OH and Boc-Pro-OH.

[0096] (3) Add 10 mL of deprotection reagent (TFA: H2O: Tis = 95:2.5:2.5) to the peptide reaction bottle and react at room temperature for 2.5 h to remove the amino acid side chain protecting groups. Collect the reaction solution, concentrate under reduced pressure, and cool in an ice water bath. Add cold ether dropwise to precipitate to obtain a crude linear peptide PF-15. Purify it through semi-preparative high performance liquid chromatography to obtain PF-15 as a white powder.

[0097] Test Example 1: Characterization of the physical and chemical properties of antimicrobial peptide PF-15

[0098] 1. Nuclear Magnetic Resonance Analysis

[0099] The structure of the antimicrobial peptide PF-15 prepared above was characterized by nuclear magnetic resonance spectroscopy as follows:

[0100] 1H NMR(600MHz,DMSO–d6)δ9.48(s,1H),8.58–8.51(m,2H),8.46–8.37(m,1H),8.34(d,J=8.1Hz,1H),8.22–7.98(m,3H),7.96–7.88(m,2H),7.80(ddt,J=49.1,16.3,7.2Hz,3H),7.65(tdd,J=28.1,14.5,7.3Hz,3H),7.22(dt,J=12.7,7.1Hz,10H),7.16(t,J=8.6Hz,5H),4.97(d,J=8.6Hz,1H),4.74(p,J=7.2Hz,1H),4.46–4.41(m,1H),4.37(t,J=6.0Hz,2H),4.29(ddp,J=34.6,21.0,7.8,7.3Hz,8H),4.18(p,J=6.2,5.3Hz,1H),4.09–4.03(m,1H),3.59–3.46(m,6H),3.22(dt,J=16.2,7.9Hz,4H),3.07(tdd,J=19.8,11.0,5.7Hz,7H),2.97–2.92(m,1H),2.89–2.79(m,2H),2.79–2.70(m,2H),2.62(q,J=7.0Hz,2H),2.28(t,J=8.0Hz,2H),2.16(h,J=8.6,6.7Hz,1H),2.06–1.93(m,4H),1.88(dt,J=13.9,6.9Hz,1H),1.80(tq,J=19.5,6.7Hz,6H),1.72–1.66(m,2H),1.64(s,1H),1.63–1.55(m,2H),1.45(dq,J=31.0,11.8,10.6Hz,10H),1.33–1.29(m,1H),1.24(d,J=5.2Hz,1H),1.20–1.11(m,4H),1.10(d,J=7.6Hz,1H),1.01(dp,J=19.5,6.7,5.5Hz,2H),0.94–0.79(m,18H),0.74(ddd,J=18.4,10.1,4.5Hz,12H),0.66(dd,J=6.7,3.3Hz,6H)。

[0101] 13C NMR (151MHz, DMSO) δ172.95, 172.07, 171.67, 171.57, 171.49, 170.92, 170.82, 170.68, 1 70.64, 170.60, 170.44, 170.36, 170.26, 169.59, 168.17, 168.14, 158.78, 158.57, 156.86 , 156.83, 156.79, 137.92, 137.53, 137.07, 129.42, 129.28, 129.21, 128.05, 127.78, 126.45, 126.33, 126.14, 118.08, 116.10, 72.13, 69.36, 59.55, 59.31, 58.69, 58.50, 57.96, 5 3.29, 52.19, 51.92, 51.71, 50.59, 50.46, 46.75, 45.74, 41.36, 40.35, 40.02, 36.87, 32.04, 30.55, 30.25, 30.07, 29.75, 29.06, 28.89, 28.80, 24.97, 24.90, 24.09, 23.87, 23.84, 23.76, 23.41, 23.14, 23.11, 23.07, 22.88, 22.74, 21.96, 21.73, 21.70, 21.64, 21.53, 21.47, 21.23, 21.16, 19.16, 19.13, 19.09, 19.05, 18.55, 18.51, 18.11, 18.08, 17.90, 17.85.

[0102] The H NMR spectrum of the obtained PF-15 white powder is as follows: Figure 1 As shown, the test results are consistent with expectations.

[0103] 2. Purity and molecular weight detection

[0104] The purity of the antimicrobial peptide PF-15 prepared above was detected by high performance liquid chromatography (HPLC), and the HPLC detection conditions were: sample volume: 10 μL, detection wavelength 220 nm, flow rate: 1 mL / min. The detection results are as follows Figure 2 As shown, the purity of PF-15 detected was greater than 95%.

[0105] Furthermore, the molecular weight of the antimicrobial peptide PF-15 was determined using a mass spectrometer MS, with the parameters set as probe: ESI, flow rate: 0.2 mL / min. Figure 3 As shown, the molecular weight of the antimicrobial peptide PF-15 was 1856.35 Daltons, which was consistent with expectations.

[0106] 3. Spiral wheel diagram and spatial structure prediction

[0107] According to the peptide calculator analysis, the Grand average of hydropathicity (GRAVY) of PF-15 is 1.25, which is a basic antimicrobial peptide. Furthermore, the helical wheel diagram of the antimicrobial peptide PF-15 was constructed using the online software DrawColi 1.0, and the spatial structure of the antimicrobial peptide was simulated using the online workstation PEPFOLD 3.5.

[0108] The results are as follows Figure 4 As shown, A is the helical wheel model of the antimicrobial peptide PF-15, and B is the helical model of GS, showing that both PF-15 and GS have typical amphipathic structures, which is consistent with expectations.

[0109] Test Example 2: Antimicrobial Activity of Antimicrobial Peptide PF-15

[0110] 1. Minimum inhibitory concentration determination

[0111] The minimum inhibitory concentration (MIC) of the antimicrobial peptide PF-15 was determined by microdilution method. The specific method is as follows:

[0112] S. aureus, MRSA, E. faecium, MRSE, and hemolytic Staphylococcus aureus (Streptococcus haemolyticus, S. haemolyticus) cultured to the logarithmic growth phase were diluted to 1×10 5 CFU / mL, and add equal volumes of diluted AMPs to make the final concentrations 1μM, 2μM, 4μM, 8μM, 16μM, 32μM, 64μM, 128μM, and 3 parallel wells for each concentration. After addition, incubate in a 37°C constant temperature incubator and detect OD at 0h, 2h, 4h, 6h, 8h, 10h, 12h, and 24h. 600 The test results are shown in Table 1 and Figure 5 shown.

[0113] Table 1: Minimum inhibitory concentration of PF-15 and GS against Gram-positive bacteria (unit: μM)

[0114]

[0115] The results in Table 1 show that the MICs of the antimicrobial peptide PF-15 against Gram-positive bacteria such as S. aureus, MRSA, E. faecium, and MRSE are 8μM, 32μM, 16μM, and 4μM, respectively, and the MICs of GS against these Gram-positive bacteria are 2μM, 8μM, 2μM, and 2μM, respectively. The antibacterial activity of the two antimicrobial peptides against S. aureus is the most obvious. Furthermore, the antibacterial effects of PF-15 and GS on Staphylococcus aureus at different time periods are shown in Figure 1. Figure 6 As shown, A is PF-15 and B is GS, indicating that at a concentration of 1 / 2×MIC, the antimicrobial peptides PF-15 and GS can still exhibit certain antibacterial activity before 12 hours.

[0116] It can be seen that for S. aureus, MRSE and S. haemolyticus, the modified PF-15 can maintain an antibacterial activity similar to that of GS.

[0117] 2. Determination of minimum bactericidal concentration

[0118] The minimum bactericidal concentration (MBC) of PF-15 and GS was determined as follows: the well samples with a concentration greater than or equal to MIC were diluted and spread on LB agar plates (10 g / L peptone, 5 g / L yeast extract powder, 10 g / L NaCl, 15 g / L agar, 1 L pure water), and then the plates were placed in a 37°C constant temperature incubator, and single colonies were counted after incubation for 24 hours.

[0119] Colony growth Figure 6 As shown, the MBC of PF-15 against S. aureus and MRSA were 32μM and 64μM, respectively, which were 4 and 2 times the MIC of the corresponding strains, respectively, which was consistent with the bactericidal concentration shown by GS, that is, the MBC was 2-4 times the MIC of the corresponding strains. Therefore, it can be considered that PF-15 has good bactericidal activity in vitro.

[0120] 3. Time sterilization curve

[0121] S. aureus was cultured to the logarithmic growth phase and diluted with LB medium to a concentration of 5 × 10 6CFU / mL. Mix the antimicrobial peptides (AMPs) with the bacterial solution in equal volumes so that the final concentration of AMPs is 1×MIC, 2×MIC and 4×MIC. Collect the mixture of bacteria and AMPs at specific time points (0min, 10min, 20min, 30min, 40min, 50min and 60min), dilute the collected samples by appropriate multiples, and evenly spread them on LB agar plates. After spreading, invert and incubate in a 37°C constant temperature incubator. After incubation for 24 hours, count the single colonies on the agar plate. Determine the kinetics of antibacterial activity by analyzing the number of colonies at different time points.

[0122] The results are as follows Figure 7 As shown, A is PF-15 and B is GS. It shows that at a concentration of 4×MIC, PF-15 can achieve half lethality to S. aureus in about 50 minutes and completely kill S. aureus at 60 minutes, and has comparable antibacterial activity to GS.

[0123] 4. Determination of biofilm inhibition ability

[0124] S. aureus cultured to logarithmic phase was diluted to 1×10 5 CFU / mL, and add equal volumes of diluted AMPs to duplicate wells, so that the final concentrations of antimicrobial peptides are 1μM, 2μM, 4μM, 8μM, 16μM, 32μM, 64μM, and 128μM, respectively, and set up 3 parallel duplicate wells for each concentration. Incubate in a 37°C constant temperature incubator for 24h. After the incubation, aspirate the liquid and wash 3 times with sterile phosphate buffered saline (PBS). Add 100μL of 2.5% glutaraldehyde to each duplicate well and incubate overnight in a 37°C constant temperature incubator to fix the biofilm. After fixation, wash 3 times with sterile PBS and add 100μL of 0.4% crystal violet stain to each duplicate well and stain for 30min. After staining, aspirate the liquid and wash 3 times with sterile water and dry for 10min. Add 150 μL of anhydrous ethanol to dissolve the crystal violet dye, incubate in a 37°C constant temperature incubator for 30 min, and measure at OD570.

[0125] The results are as follows Figure 8 As shown in the figure, A is PF-15 and B is GS. It shows that at the same concentration, the biofilm inhibition rate of PF-15 is significantly higher than that of GS, and it is most significant when the antimicrobial peptide concentration is lower than 16 μM. In this concentration range, the highest inhibition rate of PF-15 on biofilm can reach 90.66%, while that of GS is only 21.37%.

[0126] It can be seen that compared with GS, PF-15 has better inhibitory ability against the biofilm formed by S. aureus.

[0127] 5. Combination Therapy

[0128] The combination therapy of the present invention was tested by the checkerboard method. Three antibiotics, Imipenem (Imp), Vancomycin (Van), and Cefotaxime (Cef), were used to evaluate the combined effect of antimicrobial peptides (AMPs). The specific method is as follows:

[0129] S. aureus at the logarithmic growth phase was diluted to 1×10 5 CFU / mL and added to the wells at 100 μL per single well. AMPs and antibiotics were diluted horizontally and vertically respectively, and 50 μL of each was added to the wells. The final concentrations of the antibiotics and AMPs were 2×MIC, 1×MIC, 1 / 2×MIC, 1 / 4×MIC, 1 / 8×MIC, and 1 / 16×MIC. Incubate in a constant temperature incubator at 37 °C for 24 h, and measure the absorbance at OD 600 after incubation. Calculate the FIC value for inhibition above 80% (for each equivalent point) according to the following formula:

[0130]

[0131] where c A联合用药 : the drug concentration of the antibiotic that produces more than 80% inhibition in the checkerboard method; c B联合用药 : the drug concentration of AMPs that produces more than 80% inhibition in the checkerboard method; MIC A : the MIC of the antibiotic against the corresponding strain; MIC B : the MIC of AMPs against the corresponding strain. FICI is equal to the minimum value of ΣFIC. If FICI ≤ 0.5, there is a synergistic effect between the two materials. If 0.5 < FICI ≤ 1, there is an additive effect between the two materials. If FICI > 1, there is no combined effect of the two materials.

[0132] The test results are shown in Table 2.

[0133] Table 2: Combination Therapy of PF-15 and GS against S. aureus and MRSA

[0134]

[0135]

[0136] According to Table 2, when PF-15 and Imp, Van, and Cef acted together on S. aureus, the FICIs were 0.25, 0.3125, and 0.125, respectively, all showing a synergistic effect. When the drugs acted together on MRSA, the FICIs were 0.75, 0.3125, and 0.1875, respectively. PF-15 could still produce synergistic effects with Van and Cef, and only Imp showed an additive effect. In contrast, the combined use of GS was not obvious. When the drugs acted together on S. aureus, the FICIs were 0.625, 0.75, and 0.125, respectively. Only Cef achieved a synergistic effect, while Imp and Van could only achieve an additive effect. When the drugs acted together on MRSA, none of the three antibiotics could produce a combined effect with GS.

[0137] Test Example 3: Biocompatibility Test of Antimicrobial Peptide PF-15

[0138] 1. Hemolytic toxicity assay

[0139] This experiment evaluates the hemolytic toxicity of antimicrobial peptides by measuring the release of hemoglobin from a 4% human red blood cell suspension. The specific method is as follows:

[0140] The whole blood collected from the vein was centrifuged (500×g, 10min, 4°C), washed 3 times with PBS and resuspended to make the red blood cell suspension concentration 8%. The 8% red blood cell suspension was added with AMPs of different concentrations in equal volumes to make the final concentrations of 1, 2, 4, 8, 16, 32, 64, and 128 μM, and incubated in a 37°C constant temperature incubator. After the incubation, centrifuged (500×g, 10min, 4°C), and the supernatant was placed at OD 450 The positive control was 1% Triton X-100 and the negative control was PBS. The hemolytic activity of the antimicrobial peptide was calculated according to the following formula:

[0141]

[0142] OD peptides is the absorbance value of the antimicrobial peptide treatment group, OD PBS is the absorbance value of the PBS-treated group, OD TritonX is the absorbance value of the TritonX-100 treated group.

[0143] Test results such as Fig. 9As shown, at 16 μM, the hemolysis rate of PF-15 on human red blood cells is only 3.21%, while the hemolysis rate of GS is as high as 9.72%, which is 3 times that of PF-15. The reason for this result is attributed to the fact that the hydrophobic amino acids Val and Leu of the two chains of GS are located on the side opposite to the two Orn cationic side chains, thereby inducing strong hydrophobicity and ultimately leading to high hemolytic toxicity. After the ring-opening modification, PF-15 can effectively adjust the amphiphilicity of GS, and according to the peptide simulation prediction, it is found that the average hydrophilicity coefficient of PF-15 is 1.25, and GS can reach 1.56. Therefore, the high hydrophobicity may cause GS to produce unnecessary hemolytic toxicity.

[0144] 2. Cell viability detection

[0145] Human umbilical vein endothelial cells (HUVECs) were cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS), 1% penicillin and streptomycin until the logarithmic growth phase. Then, cells in good cell condition were added to a 96-well microplate at a density of about 5×10 3 / 100μL. After addition, place the 96-well microplate in a CO2 incubator (37°C, 5% CO2) and incubate for 24 hours to allow attachment. After the incubation, add equal volumes of AMPs diluted with DMEM (final concentrations of 1μM, 2μM, 4μM, 8μM, 16μM, 32μM, 64μM and 128μM) to the replicate wells, with 3 parallel replicate wells for each concentration. After drug stimulation of HUVECs for 24 hours, the cell viability was determined using a cell activity kit (Cell Counting Kit-8, CCK-8). After the incubation is completed, aspirate the liquid and wash 1-2 times with PBS. Add 100μL of DMEM and 10μL of CCK-8 reagent to each replicate well, incubate for 5-6 hours, and then measure the cell viability at OD 450 The absorbance was measured and the cell survival rate of AMPs was calculated according to the following formula: The negative control group used DMEM culture medium, and the positive control used DMEM culture medium containing 10% DMSO.

[0146]

[0147] Among them, OD peptids Represents the average absorbance of each experimental group, OD NC Represents the average absorbance of CCK-8 and DMEM alone. OD BLANK Represents the mean absorbance of the negative control group containing only DMEM and HUVECs.

[0148] Test results such as Fig.10 As shown, when the drug concentration reaches 128 μM, the cell survival rate of GS is only 1.21%, while the cell survival rate of PF-15 can still reach 50.498%. Moreover, at a concentration of 32 μM and below, the highest cell survival rate of GS is only 79.69%, while the cell survival rate of PF-15 can reach more than 97%.

[0149] Based on the above experimental results of hemolytic toxicity and antibacterial activity, it can be seen that the modified PF-15 can maintain similar antibacterial activity as the parent peptide while having better biocompatibility than the parent peptide, thus having a better therapeutic index and clinical application potential.

[0150] Test example 4: Stability test of antimicrobial peptide PF-15

[0151] The serum stability experiment was conducted in 25% or 50% human serum. AMPs were mixed with equal volumes of human serum and incubated (37°C, 2h) to a final concentration of 256μM. Take 60μL of the mixture and immediately add it to 120μL of H2O / MeCN (1:3 volume ratio) solution containing 12% trichloroacetic acid. Take the supernatant after centrifugation (14000rpm, 10min, 4°C). S.aureus cultured to the logarithmic growth phase was mixed with the diluted supernatant to make the final concentration of AMPs 1, 2, 4, 8, 16, 32, 64, 128μM, with 3 parallel wells for each concentration. Incubate in a 37°C constant temperature incubator for 24h and detect MIC. The results are shown in Table 3.

[0152] Table 3: Serum stability test results of PF-15 and GS

[0153]

[0154] Through experiments simulating the peripheral blood environment, it was found that although the antibacterial activity of PF-15 was reduced to a certain extent in serum solutions of different concentrations, the overall inactivation degree was small. After incubation with 25% and 50% human serum, the MIC of PF-15 against S. aureus was 16μM and 32μM, respectively, which was only 2 and 4 times that in the LB medium environment. And after incubation with 25% and 50% human serum, the MIC of GS against S. aureus was 2 and 4 times that in the LB medium, indicating that both PF-15 and GS have good stability.

[0155] Test Example 5: Study on the antibacterial mechanism of antimicrobial peptide PF-15

[0156] 1. Effect of PF-15 on ROS in S. aureus cells

[0157] S. aureus grown to logarithmic phase was diluted to OD 600 =0.5, take 0.01g DCFH-DA and dissolve it in 1mL DMSO and mix it to make ROS working solution. Take 1μL ROS working solution and add it to 9990μL bacterial solution and incubate for 30min, mixing once every 5min. Mix AMPs and bacterial solution mixed with ROS working solution in equal volumes so that the final concentrations of antimicrobial peptides are 1μM, 2μM, 4μM, 8μM, 16μM, and 32μM, respectively. After incubation for 30min, incubate at λ 488 / λ 525 Detection at the place.

[0158] Test results such as Fig.12 As shown in the figure, A is PF-15 and B is GS. It shows that at a concentration of 8μM, PF-15 and GS have similar efficiency in promoting intracellular ROS. At 16μM and 32μM, GS promotes intracellular ROS generation more significantly, but the ROS generation efficiency of PF-15 can still reach more than 50%. High concentrations of ROS can effectively damage bacterial cell membranes and other biomacromolecules, thereby exerting a bactericidal effect.

[0159] 2. Effect of PF-15 on the integrity of S. aureus cell membrane

[0160] The S. aureus cells grown to the logarithmic phase were diluted to 1×10 8 CFU / mL, and mixed with AMPs in equal volumes to make the final concentration of antimicrobial peptides 4, 8, 16, and 32 μM, incubated for 2 h, centrifuged (8000 rpm, 10 min), and washed 3 times with PBS. Resuspended in working solution and incubated for 10 min. At OD 620 Detection.

[0161] Test results such as Fig.12 As shown in the figure, A is PF-15 and B is GS, which shows that the interaction between PF-15 and S. aureus causes damage to the cell membrane. The dye enters the cell through the damaged cell membrane and combines with the protein inside the cell to produce absorbance changes. However, GS has no significant effect on the cell membrane.

[0162] As can be seen from the above, PF-15 has a more obvious ability to destroy the integrity of cell membranes than GS.

[0163] 3. Effect of PF-15 on ATP in S. aureus cells

[0164] Using the ATP content detection kit (Solarbio, www.solarbio.com), S. aureus grown to the logarithmic phase was diluted to 2×10 5 CFU / mL, and mixed with AMPs in equal volumes to make the final concentration of antimicrobial peptides 4μM, 8μM, 16μM, and 32μM, incubated together for 2h, added 1mL of extract solution and mixed, and then ultrasonically disrupted in an ice bath (power 20W, 2s on, 1s off, 1min). Centrifuge (4℃, 10000×g, 10min) to take the supernatant, add 500μL of chloroform and shake well, centrifuge (4℃, 10000×g, 3min) to take the supernatant, and add samples as shown in Table 3.

[0165] Table 3: Reagent addition diagram

[0166]

[0167] Using a UV spectrophotometer in A 450 Detect absorbance and calculate intracellular ATP content according to the following formula:

[0168] ATP content (μmol / 10 6 cell)=△A standard÷(△A standard÷C standard)×V extraction÷5;

[0169] Where C standard is the concentration of the standard solution, 0.625 μmol / mL; V extraction is the volume of the extract, 1 mL; 5 is the total number of cells or bacteria, i.e. 5×10 6 indivual.

[0170] Test results such as Fig.13 As shown, PF-15 and GS can both inhibit the production of ATP, and there is a concentration dependence, that is, as the concentration of AMPs increases, the inhibition of ATP production inside bacteria will be more obvious.

[0171] 4. Effect of PF-15 on membrane potential of S. aureus cells

[0172] The membrane potential-sensitive cyano dye 3,3'-dipropylthiadicarbocyanine iodide (DiSC3(5)) was used to measure the cell membrane potential. S. aureus grown to the logarithmic phase was diluted to 2×10 8CFU / mL, and mixed with AMPs in equal volumes to make the final concentration of antimicrobial peptides 4, 8, 16, and 32 μM, incubated together for 2 h, centrifuged (8000 rpm, 10 min), washed with HEPES / glucose buffer (5 mM HEPES, 5 mM glucose, pH 7.0), and repeated this step 2-3 times. DiSC3(5) was added to HEPES / glucose buffer to make the final concentration of DiSC3(5) 1 μM to prepare membrane potential working solution. 1 mL of membrane potential working solution was added to the bacteria and mixed. Finally, at λ 622 / λ 670 Detection wavelength. The membrane potential is determined by staining the bacteria with a fluorescence kit, i.e. measuring the ratio of green and red fluorescence, where the ratio of green to red fluorescence is linearly related to the membrane potential dissipation rate. Adding PF-15 and GS can lead to a significant decrease in red fluorescence and an increase in green fluorescence, indicating that the membrane potential of S. aureus is significantly dissipated.

[0173] Test results such as Fig.14 As shown, PF-15 and GS can inhibit the production of ATP inside bacteria at the same time. The combined action of the two antibacterial mechanisms can seriously interfere with the normal physiological activities of bacteria and eventually lead to cell death.

[0174] 5. LTA binding ability test

[0175] Equal volumes of LTA and AMPs were obtained from S. aureus and mixed. The concentration of LTA ranged from 0 to 128 μg / mL, and the concentration of AMPs was kept at 2×MIC. 100 μL of S. aureus (logarithmic growth phase, 1×10 5 CFU / mL) and incubate for 24 h. 600 Detect absorbance at.

[0176] LTA is a polysaccharide on the cell wall of Gram-positive bacteria. Its main component is a polymer formed by ribitol or glycerol residues connected by phosphodiester bonds. AMPs can bind to LTA and insert into the bacterial outer membrane. The higher the binding ability of the two, the higher the binding ability with Gram-positive bacteria.

[0177] Test results such as Fig.15 As shown, A is PF-15 and B is GS, which shows that as the concentration of LTA increases, the antibacterial activity of PF-15 is significantly inhibited. GS only affects its antibacterial activity when the concentration of LTA is greater than 32μM. According to this result, PF-15 has a stronger binding ability with LTA than GS. Therefore, it is inferred that LTA may be a potential binding target of PF-15.

[0178] Test Example 6: In vivo antibacterial activity test of PF-15

[0179] The in vivo animal model of the present invention uses C57BL / 6 mice (6-8 weeks, female, 8 mice in a group) induced by MRSA bacteremia, and the number of single colonies in the peripheral blood of mice is detected by injecting PF-15 after infection to determine whether PF-15 has the ability to treat bacterial infectious diseases. The specific detection method is as follows:

[0180] First, a concentration of 1 × 10 8 The mice were induced with bacteremia by 0.1 mL of MRSA solution with CFU / mL. The mice were then randomly divided into the following 4 groups:

[0181] ① Negative control group: 0.1 mL of sterile PBS was injected into the tail vein;

[0182] ② Drug treatment group: tail vein injection of PF-15 (20 mg / kg, 0.1 mL);

[0183] ③ Positive control group: tail vein injection of vancomycin (20 mg / kg, 0.1 mL);

[0184] ④ Combined drug treatment group: tail vein injection of PF-15 (10 mg / kg, 0.1 mL) and vancomycin (10 mg / kg, 0.1 mL).

[0185] Then, blood was collected on the 1st, 2nd, 3rd, 4th, 5th, 6th and 7th day respectively and spread on LB agar plates for dilution and incubation (37°C, 24h) to determine the number of single colonies in the peripheral blood.

[0186] Test results such as Fig.16 As shown in the figure, Control is the negative control group, PF-15 is the drug treatment group, Van is the positive control group, and PF-15+Van is the combined drug treatment group. It shows that PF-15 has good antibacterial activity in vivo and when used in combination with Van, it can effectively reduce the dosage of antibiotics and achieve a certain combined drug effect.

[0187] In summary, the present invention provides an antimicrobial peptide PF-15 based on gramicidin S derivative design and its preparation method and application. The amino acid sequence of the antimicrobial peptide PF-15 is PVRL-dF-PVRL-dF-PVRL-dF, which has typical amphipathic and α-helical structural characteristics. The antibacterial performance test results of the antimicrobial peptide PF-15 show that the minimum inhibitory concentration of PF-15 against Staphylococcus aureus is 8μM, and the minimum bactericidal concentration is 32μM. The minimum inhibitory concentrations for other Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus, Enterococcus faecium, multidrug-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus epidermidis are 32μM, 16μM, 64μM, and 4μM, respectively. In the in vivo experiment of bacteremia induced by MRSA, PF-15 showed good antibacterial effect, and when used in combination with vancomycin, it can effectively reduce the dosage of antibiotics. Secondly, the hemolytic toxicity and cytotoxicity results of the antimicrobial peptide PF-15 showed that PF-15 showed lower hemolytic toxicity and cytotoxicity than GS, and had superior biocompatibility. In addition, in terms of antibacterial mechanism, the present invention found that PF-15 can effectively retain the antibacterial mechanism of the parent peptide, that is, it binds to the receptor protein inside the cell to inhibit the production of adenosine triphosphate while promoting the generation of reactive oxygen. PF-15 can combine with lipoteichoic acid to effectively destroy the cell membrane integrity of S. aureus to achieve an antibacterial effect, and has a wide range of application value in clinical research.

[0188] The above is a detailed description of the embodiments of the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. An antimicrobial peptide PF-15 derived from gramicidin S, characterized in that: The amino acid sequence of the antimicrobial peptide PF-15 is as follows: Pro-Val-Arg-Leu-dPhe-Pro-Val-Arg-Leu-dPhe-Pro-Val-Arg-Leu-dPhe; The antimicrobial peptide PF-15 is a linear peptide.

2. The method for preparing the antimicrobial peptide PF-15 according to claim 1, characterized in that: The peptide was prepared by solid phase synthesis.

3. Use of the antimicrobial peptide PF-15 as claimed in claim 1 in the preparation of anti-Gram-positive bacteria products.

4. The use according to claim 3, wherein the Gram-positive bacteria include at least one of Staphylococcus aureus and Enterococcus faecium.

5. The use according to claim 4, wherein the staphylococci include Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and methicillin-resistant Staphylococcus epidermidis.

6. An antibacterial drug, characterized in that: It comprises the antimicrobial peptide PF-15 or a pharmaceutically acceptable salt thereof as claimed in claim 1.

7. The antibacterial drug according to claim 6, characterized in that: It also contains antibiotics and / or pharmaceutically acceptable excipients.

Citation Information

Cited By

  • Product, system and method of cell cultivation

    US12668774B2

  • Culture media based on protein hydrolysate and a process for preparing thereof

    US12686847B2

  • Pet food, methods and devices for producing pet food

    US12772996B2